Sang Phil Yoon,Ki Seong Ko,Ha Na Yu,Hye Jung Baik,Won Kyu Yang,Jin Young Ko,So Hyun Park,Sung Bum Jung,Sung Won An,Min Hyo Ki
申请号：
US14440060
公开号：
US20150297726A1
申请日:
2013.12.27
申请国别(地区):
US
年份:
2015
代理人:
摘要：
Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups； b) at least one phospholipid； c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety； and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue.
